Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC increased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 0.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 43,095 shares of the medical research company’s stock after purchasing an additional 302 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Edwards Lifesciences were worth $3,190,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. FSA Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the third quarter valued at approximately $30,000. Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences in the third quarter worth approximately $32,000. Avior Wealth Management LLC lifted its position in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares during the last quarter. Peoples Bank KS acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at approximately $40,000. Finally, JFS Wealth Advisors LLC raised its holdings in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after buying an additional 166 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

EW stock opened at $72.41 on Friday. The stock’s fifty day simple moving average is $72.45 and its 200-day simple moving average is $70.09. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The stock has a market capitalization of $42.71 billion, a price-to-earnings ratio of 10.45, a price-to-earnings-growth ratio of 3.65 and a beta of 1.11.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on EW shares. Wolfe Research cut shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price target for the company. in a research report on Thursday, January 16th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $75.00 to $90.00 in a research note on Thursday. Royal Bank of Canada increased their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Thursday, December 5th. The Goldman Sachs Group lifted their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Finally, Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $79.19.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,000 shares of company stock valued at $2,195,180 over the last quarter. Company insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.